- Home
- INO
INO
Inovio Pharmaceuticals Inc.
as 04-01-2025 4:00pm EST
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | N/A | IPO Year: | 1998 |
| Target Price: | $12.20 | AVG Volume (30 days): | 703.5K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.50 - $13.44 | Next Earning Date: | 03-18-2025 |
| Revenue: | $217,756 | Revenue Growth: | -73.83% |
| Revenue Growth (this year): | 1105.02% | Revenue Growth (next year): | 922.41% |
Latest Inovio Pharmaceuticals Inc. News
INO Breaking Stock News: Dive into INO Ticker-Specific Updates for Smart Investing
MT Newswires
14 days ago
RBC Cuts Price Target on Inovio Pharmaceuticals to $5 From $6, Keeps Sector Perform, Speculative Risk
GuruFocus.com
14 days ago
Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Motley Fool
14 days ago
Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript
PR Newswire
15 days ago
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
MT Newswires
19 days ago
Sector Update: Health Care Stocks Higher Premarket Friday
MT Newswires
19 days ago
Inovio Pharmaceuticals Reports Interim Trial Results of DNA-Encoded Monoclonal Antibodies for COVID-19
PR Newswire
19 days ago
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
PR Newswire
21 days ago
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
Compare INO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INO Inovio Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.